大肠杆菌在PBC药物靶点筛选中的应用
By identifying and utilizing the characteristic gene combination of Escherichia coli strain PBC-EC01, diagnostic biomarkers and therapeutic targets were developed, solving the problem of early identification and precise treatment of primary biliary cholangitis and improving treatment outcomes.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
- Filing Date
- 2026-06-18
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack microbial biomarkers that can specifically identify high-risk individuals for primary biliary cholangitis, making it impossible to predict the risk of disease occurrence early. Conventional antibiotic treatment does not consider strain specificity and intestinal-urinary tract shared characteristics, lacks precise intervention strategies targeting specific pathogens, and ursodeoxycholic acid treatment is ineffective.
By isolating and identifying the Escherichia coli strain PBC-EC01, which is common to both the intestine and urinary tract, from patients with primary biliary cholangitis complicated by urinary tract infection, we found that it carries a characteristic fimbrial antigen gene combination and a short-chain fatty acid degradation gene. We developed diagnostic biomarkers and therapeutic targets based on this strain and constructed animal models to screen drugs.
It provides new diagnostic biomarkers and therapeutic targets, enabling early identification of PBC risk, precision treatment, improved treatment outcomes, and reduced non-response rate to ursodeoxycholic acid therapy.
Smart Images
Figure CN122405511A_ABST